Q3 26 Results and Key Strategic Milestones

Q3 26 RESULTS AND KEY STRATEGIC MILESTONES DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) releases its investor update for the three months to the end of December 2025 (Q3 26) today with reports on further strategic achievements to support a reinstatement of Medicare coverage of Cxbladder and the volume of Cxbladder tests processed through its laboratories. The investor update includes: • A preview of our Medicare Administrative Contractor Novitas’ Contractor Advisory Committee (CAC) meeting to be held on 20 February 12.00pm (NZST) , including an overview of what investors should look for from this important meeting. These meetings are generally convened ahead of developing new or substantially revised medical policy as a draft Local Coverage Determination (LCD). • News that Kaiser Permanente’s Real World evidence study demonstrating Cxbladder Triage’s Clinical Utility has been accepted for publication in Urology Practice and will therefore likely be able to be profiled at the CAC. The study was first previewed at the 2025 American Urological Association annual meeting. • Progress in the Medicare appeals of Cxbladder Triage tests denied reimbursement since the finalization of the Genetic testing for Oncology LCD: Specific Tests (L39365) that ended coverage of Cxbladder. In January we heard that our first hearing of four cases had been set down for 24 February 2026 just after the CAC meeting. • Total laboratory throughput (TLT) in Q3 26 fell 13.4% to 5,446 tests from 6,286 in Q2 26. US TLT was down 19.5% to 4,003 tests from 4,971 in Q2 26. APAC volumes rose 9.7% to 1,443 tests from 1,315 in Q2 26 lifted by an increase in commercial test volumes. • Confirmation that Cxbladder Triage has been endorsed as ‘meeting coverage criteria’ by Avalon Healthcare Systems, a large diagnostic intelligence provider that is used by healthcare payers and providers supporting more than 44 million US lives. This is also important evidence that can be used at the CAC. • Detail of the farewell to retiring Chair Chris Gallaher, and a profile of our new Chair Simon Flood. Pacific Edge Chief Executive Dr Peter Meintjes says in the update: “Despite the ongoing throughput challenges that have been amplified by the seasonal holiday slow down, Pacific Edge enters 2026 in the strongest position to establish enduring Medicare coverage policy in a LCD — the strategic focus for more than a decade. If successful, this will establish a materially more certain environment for reimbursement for Cxbladder by Medicare and other providers in the US." Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer. For more information: Investors: Dr Peter Meintjes Chief Executive Pacific Edge P: 022 032 1263 Media: Richard Inder The Project P: +64 21 645 643 OVERVIEW Pacific Edge: www.pacificedgedx.com Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA. Cxbladder: www.cxbladder.com Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of urothelial cancer in patients presenting with microhematuria and those being monitored for recurrent disease. The tests help improve the overall patient experience, while prioritizing time and clinical resources to optimize practice workflow and improve efficiency. Supported by over 20 years of research, Cxbladder’s evidence portfolio extends to more than 25 peer reviewed publications, and Cxbladder Triage is now included in the American Urological Association’s Microhematuria Guideline. To drive increased adoption and improved patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies designed to generate further clinical utility evidence. Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and South America. In the US, the test has been used by over 5,000 urologists who have ordered more than 130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the population via public healthcare and all residents have the option of buying the test online.